Initial testing of the multitargeted kinase inhibitor pazopanib by the pediatric preclinical testing program

Stephen T. Keir, Christopher L. Morton, Jianrong Wu, Raushan T. Kurmasheva, Peter J. Houghton, Malcolm A. Smith

Research output: Contribution to journalArticlepeer-review

27 Scopus citations

Abstract

Pazopanib is an oral angiogenesis inhibitor targeting vascular growth factor receptor-1, -2, and -3, platelet derived growth factor receptor-α, platelet derived growth factor receptor-β, and KIT that has demonstrated activity against a variety of adult cancer xenografts. Pazopanib was tested against a panel of pediatric rhabdomyosarcoma and Ewing sarcoma xenografts at a dose of 108mg/kg/day or 100mg/kg twice daily, administered orally for 28 days. While no objective responses were observed, pazopanib induced statistically significant differences in event-free survival compared to controls in approximately one-half of the sarcoma xenograft models tested. Though well tolerated, pazopanib showed limited activity against the sarcoma models evaluated, with the best tumor responses being growth delay.

Original languageEnglish (US)
Pages (from-to)586-588
Number of pages3
JournalPediatric Blood and Cancer
Volume59
Issue number3
DOIs
StatePublished - Sep 2012
Externally publishedYes

Keywords

  • Developmental therapeutics
  • Pazopanib
  • Preclinical testing

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Initial testing of the multitargeted kinase inhibitor pazopanib by the pediatric preclinical testing program'. Together they form a unique fingerprint.

Cite this